AstraZeneca PLC (AZN.L)

8,395.86 +47.86 (+0.57%) As of 2:16PM BST. Market open.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 76,100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Exec. Director	4.39M	N/A	1959
Mr. Marc Dunoyer	CFO & Exec. Director	2.45M	N/A	1952
Ms. Pam P. Cheng	Exec. Vice-Pres of Operations & Information Technology	N/A	N/A	1971
Thomas Kudsk Larsen	Head of Investor Relations	N/A	N/A	N/A
Mr. Jefrey Pott	Exec. VP of HR & Gen. Counsel	N/A	N/A	N/A
Ms. Katarina Ageborg	Exec. VP of Sustainability & Chief Compliance Officer	N/A	N/A	N/A
Dr. Menelas Pangalos	Exec. Vice-Pres of BioPharmaceuticals R&D	N/A	N/A	N/A
Dr. Ruud Dobber	Exec. Vice-Pres of BioPharmaceuticals Bus. Unit	N/A	N/A	N/A
Dr. Susan Mary Galbraith M.D., Ph.D.	Sr. VP and Head of Research, Early Devel. & Oncology R&D	N/A	N/A	1966
Dr. David B. Goldstein Ph.D.	Chief Adviser	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 1 June 2021 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.